Table 1.
OS Signal | Effect on MSCs | MSC Signal | Effect on OS | Reference |
---|---|---|---|---|
Exosomes | Increase in COLGALT2 and proliferation. | Wang et al. 2020 [28] | ||
CM 1/co-culture | Increase in MMP2/9; STAT3 activation. Increased proliferation, invasion, and metastasis. | Wang et al. 2017 [29] | ||
IL-8 (co-culture) |
Increased IL-8. | IL-8 (co-culture) |
Increased IL-8. Increased metastatic potential. |
Kawano et al. 2018 [30] |
IL-6 CM/co-culture |
Increase in MMP2/9; JAK2/STAT3 activation. Increased proliferation, migration, and doxorubicin resistance. | Lu et al. 2021 [31] | ||
MCP-1, GRO-α, and TGFβ | Mesenchymal-to-amoeboid transition. Increase in MCP-1, GRO-α, IL-6, and IL-8 in the tumor environment. |
Increased migration, invasion, and trans-endothelial migration. | Pietrovito et al. 2018 [20] |
|
OS-EVs | LINE-1 hypomethylation increased VEGF-A. | Mannerström et al. 2019 [24] | ||
CM | STAT3 activation. Promote survival and drug resistance. |
Tu et al. 2016 [25] | ||
MSC-EVs (under stress) |
Increased migration. Apoptosis resistance. | Vallabhaneni et al. 2016 [32] | ||
Co-culture | Increased TGFβ. | Co-culture IL-6 |
Increased OS proliferation, stemness & migration. | Cortini et al. 2016 [26] |
IL-6 | STAT3 activation. Increased proliferation and metastasis. | Tu et al. 2012 [33] | ||
CM/TGFβ | Increased IL-6, VEGF. Inhibit osteogenic differentiation. |
Tu et al. 2014 [34] | ||
IL-8 | CXCR1/Akt activation. Promotes metastasis. |
Du et al. 2018 [35] | ||
EVs/TGFβ | Increased IL-6. | Tumor-educated MSC | Activation of STAT3 signaling. | Baglio et al. 2017 [23] |
EVs | Cell growth under hypoxia. Activation of PI3K/AKT & HIF-1α. | Lin et al. 2019 [36] | ||
EVs | Activation of Hedgehog signaling. Tumor growth. | Qi et al. 2017 [37] |
1 CD, conditioned medium.